Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 2, 2007, Pages 162-166

  Ernst, Pierre ^a,b   Gonzalez, Anne V ^a   Brassard, Paul ^a   Suissa, Samy ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Chronic obstructive pulmonary disease; Cohort studies; Corticosteroids; Drug therapy; Inhaled therapy

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE; IPRATROPIUM BROMIDE; THEOPHYLLINE; TRIAMCINOLONE;

AGED; ARTICLE; CANADA; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; MALE; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUEBEC; RISK ASSESSMENT;

EID: 34447310860     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200611-1630OC     Document Type: Article

References (25)

1. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-1639.
2. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303.
3. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-1909.
4. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-1823.
5. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-1953.
6. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65.
7. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:842-846.
8. Van Andel AE, Reisner C, Menjoge SS, Witek TJ. Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995. Chest 1999;115:703-707.
9. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA; Department of Veterans Affairs Cooperative Study Group. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-1947.
10. Jackevicius CA, Chapman KR. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: a survey. Ann Pharmacother 1997;31:160-164.
11. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-798.
12. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-149.
13. Anonymous. Pneumonia and influenza death rates - United States, 1979-1994. MMWR Morb Mortal Wkly Rep 1995;44:535-537.
14. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2001 annual summary with detailed diagnosis and procedure date. Vital Health Stat 13 2004;153:1-198.
15. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
16. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004;169:83-88.
17. Ernst P, Baltzan M, Deschenes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006;27:1168-1174.
18. National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert panel report 2: guidelines for the diagnosis and management of asthma. 1997. National Institutes of Health Publication No. 97-4051. Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (accessed May 2007).
19. Boulet LP, Becker A, Berube D, Beveridge R, Ernst P; Canadian Asthma Consensus Group. Canadian Asthma Consensus Report, 1999. Can Med Assoc J 1999;161:S1-61.
20. Wertheimer AI. The defined daily dose system (DDD) for drug utilization review. Hosp Pharm 1986;21:233-241, 258.
21. Farr BM, Bartlett CL, Wadsworth J, Miller DL; British Thoracic Society Pneumonia Study Group. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. Respir Med 2000;94:954-963.
22. Almirall J, Bolibar I, Balanzo X, Gonzalez CA. Risk factors for community-acquired pneumonia in adults: a population-based case - control study. Eur Respir J 1999;13:349-355.
23. Lange P, Vestbo J, Nyboe J. Risk factors for death and hospitalization from pneumonia: a prospective study of a general population. Eur Respir J 1995;8:1694-1698.
24. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Arthritis Rheum 2006;54:628-634.
25. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941-955.